Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Cellu Tissue Holdings, Inc. (CLU)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Aug-26-10 | May-27-10 | Feb-28-10 | Nov-26-09 | Aug-27-09 | May-28-09 | Feb-28-09 | Nov-27-08 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues: |
| Consolidated | | 132.1 | | | | 118.9 | | |
| Tissue | 105.9 | 103.0 | | 98.6 | 107.8 | 93.5 | 100.3 | 111.1 |
| Machine-glazed paper | | 27.3 | | | | 23.6 | | |
| Other | 299.4 | | | 31.5 | 286.7 | | 28.2 | 31.9 |
| Total revenues | 405.4 | 132.1 | 124.4 | 130.1 | 394.5 | 118.9 | 128.4 | 143.0 |
| Revenue growth [+] | 2.7% | 11.1% | -3.1% | -9.0% | 196.6% | 3.8% | 8.2% | 27.5% |
| Consolidated | | 11.1% | | | | 3.8% | | |
| Tissue | -1.7% | 10.2% | | -11.3% | 4.2% | 8.9% | | 32.2% |
| Machine-glazed paper | | 15.8% | | | | -17.9% | | |
| Foam | -40.8% | -3.8% | | 27.6% | 137.2% | | | |
| Cost of goods sold | 247.8 | 120.0 | 108.1 | 109.9 | 214.3 | 99.1 | 112.4 | 126.9 |
| Gross profit | 157.6 | 12.2 | 16.3 | 20.3 | 180.3 | 19.8 | 16.0 | 16.1 |
| Gross margin | 38.9% | 9.2% | 13.1% | 15.6% | 45.7% | 16.7% | 12.5% | 11.3% |
| Selling, general and administrative | 16.6 | 5.4 | 6.7 | 5.0 | 16.2 | 5.5 | 6.8 | 5.9 |
| Other operating expenses | 131.0 | 1.0 | 1.1 | 1.1 | 118.4 | 1.1 | 0.7 | 0.6 |
| EBITDA [+] | 17.7 | 13.1 | 16.3 | 21.4 | 52.9 | 20.2 | 15.4 | |
| EBITDA growth | -66.6% | -35.0% | 6.1% | 97.1% | 739.4% | 63.4% | 61.0% | -55.6% |
| EBITDA margin | 4.4% | 10.0% | 13.1% | 16.5% | 13.4% | 17.0% | 12.0% | 7.6% |
| Depreciation | 4.4 | 6.4 | 6.7 | 6.2 | 4.0 | 5.9 | 6.0 | |
| EBITA | 13.2 | 6.8 | 9.7 | 15.3 | 48.9 | 14.3 | 9.3 | 10.9 |
| EBITA margin | 3.3% | 5.1% | 7.8% | 11.7% | 12.4% | 12.0% | 7.3% | 7.6% |
| Amortization of intangibles | 3.2 | 1.0 | 1.1 | 1.1 | 3.2 | 1.1 | 0.8 | 1.3 |
| EBIT [+] | 10.0 | 5.7 | 8.5 | 14.2 | 45.7 | 13.3 | 8.5 | 9.6 |
| EBIT growth | -78.1% | -56.9% | 0.2% | 47.4% | 731.0% | 102.9% | 127.3% | 56.0% |
| EBIT margin | 2.5% | 4.3% | 6.9% | 10.9% | 11.6% | 11.1% | 6.6% | 6.7% |
| Interest expense | 23.2 | 7.5 | 39.6 | 8.5 | 31.2 | 6.5 | 6.8 | 6.9 |
| Interest expense | 23.2 | 7.5 | 39.6 | 8.5 | 31.2 | 6.5 | 6.8 | 6.9 |
| Other income (expense), net [+] | -0.1 | -0.2 | 26.7 | -0.3 | -0.3 | -0.3 | 0.3 | 0.0 |
| Gain (loss) on foreign currency transactions | 0.1 | -0.2 | 0.0 | -0.1 | -0.4 | -0.4 | 0.1 | 0.1 |
| Other | 0.1 | 0.0 | | | -0.4 | 0.0 | | 0.0 |
| Pre-tax income | -13.2 | -2.0 | -4.3 | 5.4 | 14.2 | 6.4 | 2.1 | 2.7 |
| Income taxes | -4.2 | -0.6 | -1.1 | 3.4 | 6.4 | 4.1 | -1.9 | 0.9 |
| Tax rate | 32.0% | 31.9% | 24.6% | 62.6% | 45.3% | 63.9% | | 32.9% |
| Net income | -9.0 | -1.3 | -3.3 | 2.0 | 7.7 | 2.3 | 4.0 | 1.8 |
| Net margin | -2.2% | -1.0% | -2.6% | 1.5% | 2.0% | 1.9% | 3.1% | 1.3% |
| |
| Basic EPS [+] | ($0.22) | ($0.07) | ($0.18) | $20,000.11 | $0.22 | $0.13 | $0.23 | $18,387.46 |
| Growth | -200.5% | -150.5% | -181.0% | 8.8% | | | 65.8% | |
| Diluted EPS [+] | ($0.22) | ($0.07) | ($0.18) | $20,000.11 | $0.22 | $0.13 | $0.23 | $18,387.46 |
| Growth | -200.5% | -150.5% | -180.9% | 8.8% | | | 65.8% | |
| |
| Shares outstanding (basic) [+] | 40.4 | 20.1 | 17.7 | 0.0 | 34.9 | 17.4 | 17.4 | 0.0 |
| Growth | 15.7% | 15.5% | 1.4% | 0.0% | | | 0.0% | |
| Shares outstanding (diluted) [+] | 40.4 | 20.1 | 17.7 | 0.0 | 34.9 | 17.4 | 17.4 | 0.0 |
| Growth | 15.7% | 15.5% | 1.5% | 0.0% | | | 0.0% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|